What Researchers Did
Researchers evaluated intratympanic dexamethasone (ITD) as initial therapy for idiopathic sudden sensorineural hearing loss (ISSHL) in 66 patients and investigated dexamethasone distribution in the inner ears of rats.
What They Found
Intratympanic dexamethasone (ITD) therapy resulted in a 77.27% good prognosis rate, which was not significantly different from the 81.82% observed in the control group. Animal studies showed that higher dexamethasone concentrations (10 and 20 mg/ml) led to greater local concentration and longer duration in the inner ear.
What This Means for Canadian Patients
For Canadian patients with idiopathic sudden sensorineural hearing loss, intratympanic dexamethasone at 5mg/ml may not offer additional benefit over standard systemic steroid treatment. Future research on optimizing drug delivery with higher concentrations could potentially improve outcomes.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The human trial only tested one concentration (5mg/ml) of intratympanic dexamethasone, which the animal study suggested might not be optimal.